Fig. 4. Secondary endpoints - mean/median percent change from baseline in BMD in total hip, femoral neck, and trochanter and in bone turnover markers, s-CTX and s-PINP. BMD measurements consisted of last observation carried forward (LOCF) values, and bone turnover marker measurements consisted of observed values. Error bars for BMD endpoints are 95% confidence intervals for the mean percent change from baseline BMD. Error bars for bone turnover markers are (Q1, Q3). Baseline for the placebo → denosumab group is the end of double-blind phase. BMD, bone mineral density; s-CTX, serum C-terminal telopeptide of type I collagen; s-PINP, serum procollagen type I N-terminal propeptide.
